Biotech company Regeneron (NASDAQ:REGN) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 3.7% year ...

Bayer has overturned a ruling that it brought discredit on the pharma industry. | Bayer has overturned a ruling that it brought discredit on the pharma industry. Accused of “warming the market” for a ...

Regeneron Pharmaceuticals, Inc. REGN reported first-quarter 2025 adjusted earnings per share (EPS) of $8.22, which missed the Zacks Consensus Estimate of $8.43. The reported figure was down 14% from ...

Regeneron missed Wall Street estimates for first-quarter results on Tuesday, hurt by waning demand for its blockbuster eye ...

If approved, EYLEA HD would be the first and only treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period – halving the number of injections that are ...

Shares of Regeneron Pharmaceuticals are trading higher Wednesday recovering after a drop on Tuesday that followed the release ...

The CRL did not identify any issues with the safety or efficacy of EYLEA HD in its approved indications and dosing regimens. The FDA did not agree with Regeneron’s proposal to add additional ...

Yes, the erosion of EYLEA’s exclusivity and IP is concerning, and for good reason. However, the company’s financials, recent legal rulings, capital allocation and late-stage pipeline assets ...

Berlin: Bayer has submitted an application to the Japanese Ministry of Health, Labour and Welfare (MHLW) seeking approval of ...